Bridgefront Capital’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
Other funds holding GILD
Bridgefront Capital's GILD Position: Q3 2026 in Review
Bridgefront Capital reduced its Gilead Sciences (GILD) stake by 57% in Q3 2026, selling an estimated $1.23M and leaving 6,698 shares worth $998K. The position accounts for 0.24% of the portfolio, ranked #138.
Bridgefront Capital first reported a position in GILD in Q2 2021 and has held it in 7 quarters since. The position peaked at $1.95M in Q2 2026. 2,357 funds tracked by Wall St. Rank hold GILD as of Q3 2026.
- Bridgefront Capital held 6,698 shares of Gilead Sciences worth $998K as of Q3 2026.
- Bridgefront Capital sold 8,750 Gilead Sciences shares in Q3 2026, an estimated $1.23M.
- Gilead Sciences made up 0.24% of Bridgefront Capital's portfolio in Q3 2026, its #138 holding.
- Bridgefront Capital first reported a position in Gilead Sciences in Q2 2021 and has held it in 7 quarters since.
- Bridgefront Capital's Gilead Sciences position peaked at $1.95M in Q2 2026.
- 2,357 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.
Based on Bridgefront Capital's 13F filing for Q3 2026, filed 16 Nov 2026.